Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
Mem. Inst. Oswaldo Cruz
;
109(6): 828-833, 09/09/2014. tab, graf
Article
Dans Anglais
| LILACS
| ID: lil-723996
ABSTRACT
This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Trypanocides
/
Trypanosoma cruzi
/
Maladie de Chagas
/
Découverte de médicament
Type d'étude:
Guide de pratique
langue:
Anglais
Texte intégral:
Mem. Inst. Oswaldo Cruz
Thème du journal:
Médecine tropicale
/
Parasitologie
Année:
2014
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Universidade de São Paulo/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS